To study community pharmacists' level of knowledge on medication safety in patients with hepatic impairment and their practice in caring for these patients.
| INTRODUCTION
Patients with hepatic impairment are prone to develop adverse drug reactions due to changes in the pharmacokinetics and pharmacodynamics of medicines. 1, 2 Research showed that nearly 30% of patients with liver cirrhosis, the advanced stage of all chronic liver diseases, experience adverse drug reactions. 3 A Dutch study showed that almost 2/3 of patients with liver cirrhosis used potentially unsafe drugs. 4 In addition, a recent study among 57 patients with cirrhosis identified a median of 6 medication-related problems per patient. 5 Almost 60% of these problems could be resolved during a pharmacistled medication review. This suggests that pharmacists, as medication experts, could play a key role in preventing and resolving medicationrelated problems in this vulnerable patient group.
A barrier for pharmacists to fulfil this role was the lack of concrete prescribing recommendations for patients with hepatic impairment and deficiencies in the information for these patients in the product labels. [6] [7] [8] [9] However, in 2018, practical guidance for safe drug use in this specific patient group was published. 10, 11 In the Netherlands, the website containing all guidance (www.drugsinlivercirrhosis. org) has been available since 2017. Furthermore, the guidance was integrated in all relevant clinical decision support systems (CDSS) used in Dutch community pharmacies. Implementing changes in practice may take time and pharmacists might encounter difficulties in practice. 12 For example, a substantial part of the recommendations depends on the severity of hepatic impairment, being expressed using the Child-Turcotte-Pugh classification. 10, 13 Therefore, it is important that this severity class is registered in the medical and pharmaceutical record of a patient and exchanged between relevant healthcare providers. In addition, pharmacists need to be familiar with the recommendations and have sufficient knowledge about the topic to be able to interpret and apply the information in their practice.
Previous work focussed on knowledge and practices of physicians in prescribing analgesics for patients with chronic liver disease. [14] [15] [16] Little is known about the knowledge of community pharmacists on safe medication use in patients with hepatic impairment. A few studies have described the care provided by pharmacists for a subgroup of patients: those with viral hepatitis C, [17] [18] [19] but those studies focussed on clinical pharmacists or described care in only 1 clinic. Therefore, this study aimed to determine the level of knowledge of community pharmacists on medication safety in patients with hepatic impairment and their practice in caring for this patient group.
| METHODS

| Study setting
In the Netherlands, patients are usually registered with 1 general practitioner (GP) and 1 community pharmacy. 20 The GP keeps a medical record per patient and the pharmacist a pharmaceutical record. In general, these are electronic records which operate a CDSS. Clinical risk management of medication use is an important activity of Dutch community pharmacists. 21 In case the CDSS generates a medication safety alert (e.g. contraindications, drug-drug interactions), the pharmacist assesses the clinical relevance of the alert and if applicable, takes action (e.g. inform the patients, adjust the dose or switch drugs in cooperation with the GP).
| Study population
We conducted a cross-sectional survey among pharmacists from the Utrecht Pharmacy Practice network for Education and Research (UPPER) network. The UPPER network consists of 1545 community pharmacies, representing 75% of all community pharmacies in the Netherlands at the time the survey was performed. 22 An invitation for the pharmacist to participate in the electronic survey was sent in March 2018, one and a half years after the implementation of the first safety and dosing advices in cirrhosis. 10 A reminder was sent 2 weeks later and the questionnaire was closed 2 weeks thereafter. As an incentive, all respondents were given the option to receive additional information about "pharmaceutical care in patients with hepatic impairment" by providing their email address at the end. The survey was conducted with Survey Monkey software. It was approved by the UPPER Institutional Review Board of Utrecht University (number: UPF1801).
| Survey
The survey consisted of 27 questions covering 2 main topics: knowledge and current practice and can be found in the Supplementary What is already known about this subject • Patients with hepatic impairment have an increased risk of medication-related problems due to alterations in pharmacokinetics and pharmacodynamics of medicines.
• Pharmacists could play a key role in preventing and resolving medication-related problems in this vulnerable patient group.
What this study adds
• Community pharmacists frequently evaluated the safety of a medicine in patients with hepatic impairment.
• The level of knowledge of pharmacists on medication safety in patients with hepatic impairment was limited and more education on the topic is needed and wanted.
• Community pharmacists experienced limited access to relevant patient data (e.g. diagnosis and severity of hepatic impairment) which may adversely affect their practice.
Data. The questionnaire was developed by the authors with expertise in hepatic impairment and pharmacy practice, and piloted among 13 pharmacists. We refined the questionnaire based on the pilot: we adjusted the formulation of some answers and changed the order of the questions slightly. 
| Data analysis
We used both descriptive and inferential statistics to analyse the data.
Due to missing values, the number of respondents per question varied and, where appropriate, the absolute number of respondents per questions was listed. In total, <5% of items were missing. Due to the low rate scoring of some of the multiple-choice questions, we merged responses from selected questions into fewer categories. The statements on knowledge were recoded from a 5-point Likert scale into a 3-level scale: strongly disagree/disagree, neutral, agree/strongly agree.
The answers on the frequency of a medication safety alert were recoded into often (daily/weekly) and rarely (monthly/less than once a month). The answers countryside and village from the variable location of pharmacy were combined into village or countryside. Answers to the question about the community pharmacy registration were merged into registered as community pharmacist and not (yet) registered as community pharmacist.
The outcome of the knowledge test was the number of correctly answered questions, with a maximum of 6. Univariate analyses were performed for all potential explanatory variables. The variables age and years of practice were highly correlated and therefore only 1 variable (i.e. years of practice) was included in the analysis. After univariate analyses, variables with P-values <.25
were included in multiple linear regression analysis. Cases with missing data were deleted pairwise. A P-value <.05 was considered statistically significant. The analyses were performed with SPSS, version 25.
| RESULTS
In total, 338 pharmacists (22%) completed the survey of the 1545 pharmacies the invitation was sent to. The characteristics of the respondents are presented in Table 1 . Respondents were predominantly female pharmacists, working in a community pharmacy in an urban area.
| Knowledge
Respondents were asked about their self-perceived knowledge on medication safety in hepatic impairment (Figure 1 In multiple linear regression analysis, 3 variables were associated with the total knowledge score ( Table 3 ). Higher knowledge scores were associated with postgraduate education or a pharmacotherapy meeting on hepatic impairment (P < .001) and familiarity with the new recommendations or website (P < .001). A higher total knowledge score was also negatively correlated to years of practice (P < .001). 
| DISCUSSION
This study is unique in assessing community pharmacists' level of knowledge on medication safety in patients with hepatic impairment and their practice in caring for these patients. We demonstrated that 70% of the respondents evaluated the safety of a medicine in a patient with hepatic impairment at least once a week and <80% consulted a prescriber in the past 6 months with a medication safety question.
However, the pharmacists' knowledge level-subjective and objectivewas insufficient and they expressed a wish for additional education.
Furthermore, pharmacists experienced difficulties in caring for these patients due to problems in the contact with prescribers and limited access to essential patient data, like the severity of hepatic impairment. hepatic function. In addition, a large proportion of pharmacists was not able to give correct advice on analgesic use in severe cirrhosis.
Knowledge of pharmacists on this topic does not seem to have been assessed previously, yet a few studies evaluated physicians' practices in prescribing analgesics in patients with cirrhosis. [14] [15] [16] These studies found similar results: an overall limited knowledge on the topic. Possible explanations for this finding are that medication safety in hepatic impairment is a rather complex topic. Gastroenterologists, specialized in caring for these patients, also knew more often which analgesic was safe to prescribe compared to nongastroenterologists. 14 Pharmacists with less years in practice scored higher on the knowledge test. Previous studies assessing healthcare professionals' knowledge on other topics (e.g.
[pharmaco]genetics) also showed that more recent graduation was related to higher knowledge scores. 23, 24 Recent graduates probably remember most from the education When consulting prescribers about patients with hepatic impairment, more than half of the pharmacists experienced difficulties during that contact. One of the difficulties mentioned was the lack of relevant patient information, i.e. data on the diagnosis and the sever- that pharmacists were able to give better pharmaceutical support when they had a more complete overview of a patient's medical record. 25 Furthermore, a review on clinical decision support noted that drug-disease interaction alerts could only work if the diagnoses and conditions of a patient, even as the degree of impairment have been accurately entered into the medical or pharmaceutical record of a patient. 26 Efforts are needed to improve exchange of these patient data. 
| Limitations
| Implications for practice and future research
The results of this study indicate a compelling need for more education on medication safety in patients with hepatic impairment. It is recommended to provide basic knowledge and create awareness for this patient group during the pharmacy and medicine undergraduate studies and provide more advanced practice-based education in a postgraduate course. In a couple of years, this study and especially the knowledge test could be repeated to evaluate improvement. In further research, one could also study the actual care provided by the pharmacists. For example, by assessing how pharmacists manage alerts in their CDSS on medication safety in patients with hepatic impairment or by examining if pharmacists ask their customers about liver disease before they recommend a nonsteroidal anti-inflammatory drug.
To improve medication safety in patients with hepatic impairment, pharmacists and prescribers can be supported by their CDSS. 26 The practical guidance on medication safety in patients with hepatic impairment was published in English, yet only integrated in CDSS in the Netherlands. 10 This study provides valuable insights for other countries that want to integrate decision support for safe use of medication in hepatic impairment. To make optimal use of clinical decision support, the exchange of the diagnosis and severity of hepatic impairment between healthcare professionals needs to be improved. Pharmacotherapy meetings between GPs and pharmacists can help. These meetings could be used to discuss practicalities limiting the exchange of the diagnosis and severity of hepatic impairment and to improve involvement and knowledge among participants. Previous studies have shown the positive impact of high-quality pharmacotherapy meetings in optimizing pharmacotherapy. 32, 33 Medication-related problems are very common in patients with cirrhosis. A recent single-centre trial showed that more than half of medication-related problems could be resolved by a pharmacist-led medication review. 5 These results are promising and the guidance we developed can support pharmacists. However, for large-scale implementation of pharmacists-led medication reviews in these patients, there are still some barriers to overcome as we demonstrated in this study.
| CONCLUSION
We showed that the level of knowledge of community pharmacists on medication safety in patients with hepatic impairment is low and that additional education is needed and wanted. The majority of pharmacists encounter patients with hepatic impairment regularly; however, when providing care in these patients they frequently experience difficulties in the contact with other healthcare professionals and lack essential patient information. If these issues are resolved, pharmacists can play a more active role in ensuring safe and optimal medication use and prevention of medication-related problems in patients with hepatic impairment.
